Active Ingredient History
Levocarnitine propionate or Propionyl L-carnitine (PLC) is the propionyl ester of L-carnitine. Propionyl-L-carnitine stimulates energy production in ischaemic muscles by increasing citric acid cycle flux and stimulating pyruvate dehydrogenase activity. The free radical scavenging activity of the drug may also be beneficial. Propionyl-L-carnitine improves coagulative fibrinolytic homeostasis in vasal endothelium and positively affects blood viscosity. It exhibits a high affinity for the muscle enzyme, carnitine acyl transferase, and as such readily converts into propionyl-CoA and free carnitine. Most studies of the therapeutic use of PLC are focused on the prevention and treatment of ischemic heart disease, congestive heart failure, hypertrophic heart disease, and peripheral arterial disease. PLC is marketed under the trade name Dromos®. It is indicated for patients with peripheral arterial occlusive disorders and for exercise intolerance enhancement in patients with chronic congestive heart failure. Dromos is marketed in Italy. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Acidosis, Lactic (Phase 4)
Acquired Immunodeficiency Syndrome (Phase 4)
Acute Kidney Injury (Phase 3)
Anemia (Phase 4)
Anemia, Sickle Cell (Phase 4)
Antioxidants (Phase 4)
Arthritis, Rheumatoid (Phase 3)
Asthma (Phase 3)
Atrial Fibrillation (Phase 3)
beta-Thalassemia (Phase 3)
Body Weight Changes (Phase 2)
Breast Neoplasms (Phase 4)
Bronchiectasis (Phase 2)
Carbon Monoxide Poisoning (Phase 2)
Carnitine (Phase 4)
Clozapine (Phase 2)
Cognitive Aging (Phase 2/Phase 3)
Colitis, Ulcerative (Phase 3)
Coronary Artery Disease (Phase 2/Phase 3)
COVID-19 (Phase 2/Phase 3)
Cytomegalovirus Infections (Phase 3)
Diabetes Mellitus (Phase 3)
Diabetes Mellitus, Type 2 (Phase 2)
Diet Therapy (Early Phase 1)
DNA Damage (Phase 1/Phase 2)
Drug-Related Side Effects and Adverse Reactions (Early Phase 1)
Dyslipidemias (Phase 3)
Endocrine System Diseases (Phase 1/Phase 2)
Enteral Nutrition (Phase 1)
Familial Primary Pulmonary Hypertension (Phase 1)
Fatigue (Phase 3)
Functional Status (Phase 2/Phase 3)
Healthy Volunteers (Early Phase 1)
Heart Disease Risk Factors (Phase 3)
Heart Diseases (Phase 4)
Heart Failure (Phase 2/Phase 3)
Heart Septal Defects, Ventricular (Phase 1)
Hemodialysis, Home (Phase 3)
Hepatitis B (Phase 4)
HIV Infections (Phase 4)
Hyperbilirubinemia (Phase 2)
Hyperthyroidism (Phase 3)
Hypertrophy, Left Ventricular (Phase 1)
Hypotension (Phase 4)
Hypothyroidism (Phase 4)
Infant, Premature, Diseases (Phase 2/Phase 3)
Infertility, Male (Phase 4)
Insulin Resistance (Phase 3)
Intermittent Claudication (Phase 4)
Intestinal Neoplasms (Phase 3)
Keratoconjunctivitis Sicca (Phase 2)
Kidney Failure, Chronic (Phase 3)
Leukemia (Phase 3)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 3)
Lipodystrophy (Phase 4)
Lung Diseases (Phase 1)
Metabolic Syndrome (Phase 3)
Metabolism (Phase 2/Phase 3)
Multiple Sclerosis (Phase 3)
Muscle Weakness (Phase 4)
Muscular Atrophy, Spinal (Phase 3)
Myelodysplastic Syndromes (Phase 2/Phase 3)
Neoplasms (Phase 3)
Neurodevelopmental Disorders (Phase 2/Phase 3)
Non-alcoholic Fatty Liver Disease (Phase 2)
Pancreatic Neoplasms (Phase 3)
Paresthesia (Phase 3)
Patient Compliance (Phase 2)
Pediatric Obesity (Phase 3)
Peripheral Arterial Disease (Phase 4)
Peripheral Vascular Diseases (Phase 4)
Polycystic Ovary Syndrome (Phase 4)
Postpoliomyelitis Syndrome (Phase 3)
Premature Birth (Phase 4)
Pulmonary Arterial Hypertension (Phase 1)
Pyelonephritis (Phase 3)
Renal Dialysis (Phase 4)
Renal Insufficiency (Phase 3)
Respiratory Insufficiency (Phase 4)
Sarcopenia (Phase 2/Phase 3)
Semen Analysis (Phase 4)
Sepsis (Phase 3)
Shock, Septic (Phase 3)
Signs and Symptoms (Phase 4)
Sjogren's Syndrome (Phase 2)
Spinal Cord Injuries (Phase 2)
Spinal Muscular Atrophies of Childhood (Phase 1/Phase 2)
Vascular Stiffness (Phase 3)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
